These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 21905944)
61. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. Suarez F; Lortholary O; Buland S; Rubio MT; Ghez D; Mahé V; Quesne G; Poirée S; Buzyn A; Varet B; Berche P; Bougnoux ME J Clin Microbiol; 2008 Nov; 46(11):3772-7. PubMed ID: 18845828 [TBL] [Abstract][Full Text] [Related]
62. Early diagnosis of invasive mould infections and disease. Lamoth F; Calandra T J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i19-i28. PubMed ID: 28355464 [TBL] [Abstract][Full Text] [Related]
63. Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases. Cesaro S; Stenghele C; Calore E; Franchin E; Cerbaro I; Cusinato R; Tridello G; Manganelli R; Carli M; Palù G Mycoses; 2008 Nov; 51(6):497-504. PubMed ID: 18331444 [TBL] [Abstract][Full Text] [Related]
64. Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Izumikawa K; Yamamoto Y; Mihara T; Takazono T; Morinaga Y; Kurihara S; Nakamura S; Imamura Y; Miyazaki T; Nishino T; Tsukamoto M; Kakeya H; Yanagihara K; Mine M; Yasuoka A; Tashiro T; Kohno S Med Mycol; 2012 Nov; 50(8):811-7. PubMed ID: 22568603 [TBL] [Abstract][Full Text] [Related]
65. Galactomannan on the stage: prospective evaluation of the applicability in routine practice and surveillance. Tanriover MD; Ascioglu S; Altun B; Uzun O Mycoses; 2010 Jan; 53(1):16-25. PubMed ID: 20091935 [TBL] [Abstract][Full Text] [Related]
66. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Kaneko M; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M J Antimicrob Chemother; 2008 Feb; 61(2):411-6. PubMed ID: 18055488 [TBL] [Abstract][Full Text] [Related]
67. Invasive aspergillosis in patients with underlying liver cirrhosis: a prospective cohort study. Prattes J; Hoenigl M; Krause R; Buzina W; Valentin T; Reischies F; Koidl C; Zollner-Schwetz I Med Mycol; 2017 Nov; 55(8):803-812. PubMed ID: 28431001 [TBL] [Abstract][Full Text] [Related]
68. Invasive aspergillosis in children with hematological malignancies. Ozen M; Dündar NO Expert Rev Anti Infect Ther; 2011 Mar; 9(3):299-306. PubMed ID: 21417869 [TBL] [Abstract][Full Text] [Related]
70. Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients. Sabbah R; Korem M; Shaulov A; Aumann S; Nachmias B Acta Haematol; 2023; 146(5):358-365. PubMed ID: 37231768 [TBL] [Abstract][Full Text] [Related]
71. Six-year experience with GM test in hematological patients in a public Brazilian tertiary hospital. Conterno LO; Trabasso P; Resende MR; Paschoali PS; Pascucci LB; Moretti ML Braz J Infect Dis; 2024; 28(1):103718. PubMed ID: 38336355 [TBL] [Abstract][Full Text] [Related]
72. Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Morrissey CO; Chen SC; Sorrell TC; Bradstock KF; Szer J; Halliday CL; Gilroy NM; Schwarer AP; Slavin MA Leuk Lymphoma; 2011 Feb; 52(2):179-93. PubMed ID: 21281234 [TBL] [Abstract][Full Text] [Related]
73. Cross-reactivity in the Platelia™ Aspergillus enzyme immunoassay caused by blastomycosis. Van Der Veer J; Lewis RJ; Emtiazjoo AM; Allen SD; Wheat LJ; Hage CA Med Mycol; 2012 May; 50(4):396-8. PubMed ID: 21939346 [TBL] [Abstract][Full Text] [Related]
74. Design issues in studies evaluating diagnostic tests for aspergillosis. Marr KA; Leisenring W Clin Infect Dis; 2005 Sep; 41 Suppl 6():S381-6. PubMed ID: 16108003 [TBL] [Abstract][Full Text] [Related]
75. Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis. Kovanda LL; Desai AV; Hope WW J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):143-151. PubMed ID: 28181136 [TBL] [Abstract][Full Text] [Related]
76. Utility of galactomannan diagnostic assay in rhino-orbito-cerebral mycosis in COVID-19 patients. Chatterjee K; Taneja J; Agarwal C; Sasidharan J; Das A; Pandey A Indian J Med Microbiol; 2024; 48():100557. PubMed ID: 38447858 [TBL] [Abstract][Full Text] [Related]
77. Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis. Nucci F; Nouér SA; Capone D; Nucci M Clin Microbiol Infect; 2018 Oct; 24(10):1105.e1-1105.e4. PubMed ID: 29787890 [TBL] [Abstract][Full Text] [Related]
79. Naturotherapy as a potential source of mould infections in patients with haematological malignancies. Parize P; Angebault C; de Fonbrune FS; Suarez F; Lecuit M; Lortholary O; Bougnoux ME J Hosp Infect; 2013 Oct; 85(2):163-4. PubMed ID: 23954112 [No Abstract] [Full Text] [Related]
80. Beyond biomarkers: How enhanced CT imaging can improve the diagnostic-driven management of invasive mould disease. Stanzani M; Sassi C; Battista G; Lewis RE Med Mycol; 2019 Jun; 57(Supplement_3):S274-S286. PubMed ID: 31292659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]